Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackrock Inc (BLK) vs Viatris Inc (VTRS) Price & Performance

Blackrock IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Blackrock Inc vs Viatris Inc — how do they compare? Blackrock Inc trades at $1,154.13 (market cap $177.92B), while Viatris Inc trades at $16.31 (market cap $18.69B). The key difference: Blackrock Inc is far larger — about 9.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.

BLKVTRS
Market Cap
$177.92B$18.69B
Volume
641,547
Sector
FinancialsHealth
52-Week High
$1.20K$17.86
52-Week Low
$922.90$9.49
Enterprise Value
$179.02B$30.80B
Dividend Yield
2%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackrock Inc

BlackRock (BLK) trades at $1,153.57, up 1.96% today, reflecting strong momentum. The stock shows bullish technical signals with consistent earnings beats in recent quarters, including Q2 2026 EPS of $13.91 versus $12.69 expected. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights BlackRock's involvement in a $500 billion AI financing initiative with partners like Apollo and Nvidia, signaling strategic growth avenues.

The outlook remains positive with a consensus price target of $1,350, implying 17% upside. Key opportunities include robust analyst support (79% buy ratings) and dividend stability, while risks involve legal investigations into mutual fund practices and volatile cash flows, with net cash flow negative $1.29 billion in 2025. Investors should weigh solid fundamentals against regulatory and execution risks.

Viatris Inc

Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.

Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackrock Inc

BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.

Read more on BLK

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS